Clinical Trials on Refractory Tumor in New Zealand

Total 3654 results

Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Tumors | Incurable Platinum Refractory Germ Cell Tumors

United States
Proacta, Incorporated

Completed

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand
Eli Lilly and Company
Children's Oncology Group

Completed

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Recurrent Tumor | Pediatric Solid Tumor | Refractory Tumor | CNS Malignancies

United States
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
Eli Lilly and Company

Completed

Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Cancer | Refractory Solid Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
HotSpot Therapeutics, Inc

Recruiting

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Solid Tumor, Adult | Relapsed Cancer | Refractory Cancer

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Refractory Solid Tumors | Advanced Relapsed Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Relapsed Solid Tumor | Refractory Solid Tumor

United States, Canada, France, Australia, Belgium, Germany, Spain, Italy
Novartis Pharmaceuticals

Terminated

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Advanced Solid Tumors

New Zealand
Athenex, Inc.
PharmaEssentia; Zenith Technology Corporation Limited

Completed

A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Solid Tumor

New Zealand, Taiwan, Australia
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
Stanford University
Amgen; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children (POE14-01)

Refractory Leukemia | Refractory Solid Tumors | Relapsed Solid Tumors | Relapsed Leukemia

United States, Canada
Australian & New Zealand Children's Haematology...
National Health and Medical Research Council, Australia; Secura Bio, Inc.

Terminated

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH)

Rhabdoid Tumor | Atypical Teratoid/Rhabdoid Tumor | Malignant Rhabdoid Tumor | Recurrent Brain Tumor, Childhood

Australia, New Zealand, United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)

Relapsed or Refractory Solid Tumors

United States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
National Cancer Institute (NCI)

Completed

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Pineoblastoma | Recurrent Medulloblastoma | Refractory Medulloblastoma | Refractory Peripheral Primitive Neuroectodermal Tumor | Central Nervous System Neoplasm | Recurrent Primitive Neuroectodermal Tumor

United States, Canada, Puerto Rico, Australia, New Zealand
Monopteros Therapeutics Inc.

Recruiting

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Proacta, Incorporated

Completed

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand, United States
Athenex, Inc.
PharmaEssentia; Zenith Technology Corporation Limited

Completed

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Solid Tumor

New Zealand, United Kingdom, Taiwan, Australia
New York Medical College

Terminated

ODSH + ICE Chemotherapy in Pediatric Solid Tumors

Sarcoma | Neuroblastoma | Wilms' Tumor | Refractory Solid Tumor | Recurrent Solid Tumor

United States
Proacta, Incorporated

Completed

PR104 and G-CSF in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States, New Zealand
Binacea Pharma, Inc.

Recruiting

Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors

Refractory Solid Tumors

Australia
Tufts Medical Center

Terminated

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Brain Cancer | Choroid Plexus Tumors

United States, Hungary, New Zealand, Germany
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
Waikato Hospital
Wellington Hospital

Recruiting

Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma

Glioblastoma

New Zealand
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Refractory and/or Relapsed Metastatic Solid Tumors

United States
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia, China
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Lung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid Tumor

United States
Immatics US, Inc.

Completed

Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

Neoplasms | Adult Solid Tumor | Refractory Cancer | Recurrent Cancer

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Histologically-proven and Radiologically-confirmed Solid Tumors

Italy, New Zealand
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Avutometinib for People With Solid Tumor Cancers

Solid Tumor | Neuroblastoma | Solid Tumor, Adult | Primary Brain Tumor | Solid Carcinoma | Low-grade Glioma | Central Nervous System Tumor | Refractory Cancer | CNS Tumor, Adult | CNS Tumors | NF1 | Plexiform Neurofibroma | CNS Tumor, Childhood | Optic Pathway Gliomas | MAP Kinase Family Gene Mutation

United States
Memorial Sloan Kettering Cancer Center
Chugai Pharma USA

Recruiting

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Primary Extra-cranial Solid Tumor | Recurrent or Refractory Glypican 3 (GPC3)

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Solid Tumor | Metastatic Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Solid Carcinoma | Metastatic Tumor

United States
National Cancer Institute (NCI)

Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditions

United States, Canada
Sydney Children's Hospitals Network
German Cancer Research Center; Australian & New Zealand Children's Haematology... and other collaborators

Active, not recruiting

PRecISion Medicine for Children With Cancer (PRISM)

Childhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain Tumor

Australia
Processa Pharmaceuticals

Recruiting

A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Advanced Cancer | Refractory Cancer | Tumor Gastric

United States
Antisoma Research

Completed

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Malignant Melanoma

United Kingdom, New Zealand
Weill Medical College of Cornell University

Recruiting

Tissue Collection for Drug Screening and Bioanalysis

Central Nervous System Tumor | Pediatric Central Nervous System Tumor

United States
Cosmo Technologies Ltd

Recruiting

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Advanced Refractory Solid Tumors | Subjects Considered Likely to Respond to CB-03-10

United States

Clinical Trials on Refractory Tumor in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations